[-] Show simple item record

dc.contributor.authorStiles, Melissa M.eng
dc.contributor.authorMartin, Sandra I.eng
dc.date.issued2006eng
dc.description.abstractDonepezil (Aricept) has potential benefit in delaying risk of progression to Alzheimer's disease in the first year of treatment, but this benefit is not seen at 3 years. Donepezil does not improve memory for patients with mild cognitive impairment (strength of recommendation: B).eng
dc.identifier.urihttp://hdl.handle.net/10355/3425eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2006 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 55, no. 05 (May 2006)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectside effectseng
dc.subjectdementiaeng
dc.subjectAlzheimer's diseaseeng
dc.subjecttreatment costeng
dc.subject.lcshDementia -- Treatmenteng
dc.subject.lcshAlzheimer's disease -- Treatmenteng
dc.subject.lcshCognition disorderseng
dc.titleDoes treatment with donepezil improve memory for patients with mild cognitive impairment?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record